Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 21.2
Key Takeaways
Risk factor
Good trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products in China. Its products primarily focus on the rheumatism, digestion, cancer, and gynecology fields. The company offers traditional Chinese medicines, such as gynecological, rheumatic and bone pain, urology, detoxification, cardio-cerebral, digestive, respiratory, diabetes, and pediatric medication products, as...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Data is available to registered users only
